4.7 Review

Melanoma: What Do All the Mutations Mean?

Journal

CANCER
Volume 124, Issue 17, Pages 3490-3499

Publisher

WILEY
DOI: 10.1002/cncr.31345

Keywords

BRAF; cyclin-dependent kinase inhibitor 2A (CDKN2A); KIT; melanoma; mutation; NRAS; programmed cell death protein 1 (PD-1)

Categories

Funding

  1. National Institutes of Health/National Cancer Institute [K23 CA204726]
  2. James C. Bradford Jr. Endowed Fund in Melanoma Research

Ask authors/readers for more resources

Melanoma is one of the most highly mutated malignancies, largely as a function of its generation through ultraviolet light and other mutational processes. The wide array of mutations in both driver and passenger genes can present a confusing array of data for practitioners, particularly within the context of the recent revolutions in targeted and immune therapy. Although mutations in BRAF V600 clearly confer sensitivity to BRAF and mitogen-activated protein kinase kinase (MEK) inhibitors, the clinical implications of most other mutations are less often discussed and understood. In this review, we provide an overview of the high-frequency genomic alterations and their prognostic and therapeutic relevance in melanoma. (C) 2018 American Cancer Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available